Home » Topics » BioWorld Science

BioWorld Science
RSS

ANGPTL4 is elevated in peanut allergy

March 1, 2022

Discovery of novel orally bioavailable inhibitors of EGFR T790M/C797S mutants

March 1, 2022

Targeting MRGPRX2-mediated mast cell activation as a therapeutic strategy for atopic dermatitis

March 1, 2022

Study finds potential entry points to Huntington's therapy

March 1, 2022

Fibulin-2 as a novel therapeutic target in multiple sclerosis

March 1, 2022

Beijing Tide Pharmaceutical patents son of sevenless homolog 1 inhibitors

March 1, 2022

BeiGene divulges new G12C mutant GTPase KRAS inhibitors

March 1, 2022

Kira Pharmaceuticals discovers C5aR antagonists

March 1, 2022

PROTACs targeting IRAK-4 synthesized at Shanghai Leadingtac Pharmaceutical

March 1, 2022

New complement factor B inhibitors identified at Shanghai Meiyue Biotech Development

March 1, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...